Intuitive Surgical
Manufactures robotic surgical systems and services
Senior Contracts Manager
About the job
- Experience in negotiating key contractual terms and conditions.
- Knowledge of contract management best practices and commercial contract law.
- Ability to work under pressure, manage multiple projects simultaneously, and create and reset priorities as needed.
- Effective time management skills and demonstrate a positive and flexible attitude.
- Excellent verbal and written communication skills (German, French, and English) with ability to influence and persuade others.
- Ability to work independently and as part of a team
- Bachelor degree in law (e.g., erstes Staatsexamen / Diplom-Jurist / LLM).
- At least 10 years of relevant post-qualification legal or contract experience.
- Strong drafting skills, commercial mindset and attention to detail.
- Practical knowledge of GDPR and EU regulatory considerations relevant to contracts.
- Comfortable working with international contracts and cross-border transactions.
- Build strong relationships with key partners at different levels of the organization including legal, finance, and operations.
- Consult with Legal on key points of German and EU law and commercial best practice, interpreting complex terms and conditions, including IP related terms and incorporate their guidance into contract terms.
- Responsible for drafting, reviewing, and negotiating contracts that establish business relationships with suppliers.
- Analyze contracts to ensure compliance to company policy, government regulations, applicable laws, and other requirements.
- Analyze, interpret, and respond to terms presented in contracts.
- Negotiate contract terms and conditions with supplier.
- Provide guidance to internal stakeholders on contract terms, risk mitigation, and regulatory compliance.
- Develop and continuously improve contract templates, playbooks, and negotiation guidelines.
About the company
Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.
Company Size
10,001+
Company Stage
IPO
Headquarters
Sunnyvale, California
Founded
1995
Get referred to Intuitive Surgical
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 19% to $2.89 billion, with 468 da Vinci placements.
- Intuitive opened a 316,000-square-foot Penang plant, creating 1,200 jobs by 2032.
- Direct Italy-Spain-Portugal distribution expanded March 2, 2026, strengthening European control.
What critics are saying
- FDA logged a February 18, 2026 class-2 recall for da Vinci 5 software crashes.
- Johnson & Johnson's Ottava won FDA approval in summer 2026, attacking Intuitive's core.
- Medtronic Hugo and J&J Ottava commoditize robotics, breaking da Vinci's moat by 2028.
What makes Intuitive Surgical unique
- da Vinci 5 won FDA cardiac clearance on January 26, 2026.
- Ion and da Vinci generate recurring instruments, accessories, and service revenue.
- da Vinci SP earned CE mark expansion on September 15, 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.
Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.
Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.
Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.
Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.